Coherus Claims COVID Delays As It Axes Avastin Biosimilar Program
Ending Innovent’s Avastin Partnership ‘Unfortunate Business Decision’
Coherus BioSciences, juggling both biosimilar and novel biologic assets, has called time on its partnership with China’s Innovent Biologics for biosimilar Avastin – a year after shelving development of biosimilar Eylea.
